Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Blood Component Transfusion”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 325 records · Page 18Linked to original sources

[Risk management from the perspective of the hematologist].

The present paper deals with the physician's accountability during the implementation of hemotherapeutic measures. Since July 1, 1998 a Transfusion Law ('Transfusionsgesetz') regulates the clinical use of blood products in Germany in accordance with the guidelines established by the German Medical Association and the Paul Ehrlich Institute, which are regularly revised and adapted on the basis of current professional knowledge and technology. The therapeutic freedom allowed under the Code of Professional Medical Conduct is taken into account by the fact that the responsibility for hemotherapy in each individual case lies with the attending physician, no matter whether this applies to the diagnosis, the patient counselling or the administration of the transfusion itself. The administration of blood products, whether in hospital or a doctor's office, must follow certain quality-assumed rules governing transfusions as stipulated by the Transfusion Law. The responsibility for establishing regulations for hemotherapy and the introduction of a quality assurance system lies with the management of the treatment centre who appoint a specific physician as the hemovigilant ('Transfusionsverantwortlichen') who is responsible for meeting both these duties. The hemovigilant must be assisted by physicians specially appointed for transfusion measures (Transfusionsbeauftragte) who are responsible for the implementation of the hemotherapy regulations and quality assurance measures in the individual medical departments. As it is the hospital management's responsibility to ensure quality assurance, its duty also extends to monitoring the quality assurance system. Therefore a quality manager ('Qualitätsbeauftragter') will have to be appointed who must not be subject to directives. In case the management of the patient care centre does not fulfill the legal requirements or, for example, does not take action when shortcomings are discovered by the hemovigilant or quality manager that can only be dealt with by the management, then the organisational responsibility lies with the hospital management. Experience to date has demonstrated the success of the Transfusion Law. Whereas previously hospital managements have often failed to respond to suggestions for change or improvement, their attention may now be drawn to this law. This has led to blood products being increasingly used according to the same standards and keeping transfusing physicians on safe legal ground.

Blood Component Transfusion↗

Perioperative blood and blood component therapy.

This overview examines blood, blood components, their indications and contra-indications, from an anaesthetist's viewpoint. The dangers of any blood transfusion, including infection transmission and immune suppression, as well as the risks of massive and rapid transfusions, are discussed. Autologous predonation, intraoperative haemodilution and salvage are described to help prevent some of the risks of homologous blood transfusion. Preoperatively an acceptable individualised haemoglobin concentration should be calculated for each patient and a history for potential bleeding problems taken. In most patients perioperative anaemia does not adversely influence patient morbidity and mortality. However, if blood is required, 4 ml.kg-1 body weight of packed red blood cells will raise the patient's haemoglobin concentration by 1 g.dl-1. The bleeding time as a test of platelet function does not predict perioperative blood loss. However, it remains a useful test in patients with a known bleeding problem or in operations where even small amounts of bleeding increase the surgical difficulty and patient morbidity. If bleeding is due to thrombocytopaenia it is usually slow enough to allow time to check platelet number and function before ordering and transfusing them. Fresh plasma is a much overused product which should mainly be used for coagulation factor replacement, in adequate volumes (4-8 packs in dilutional coagulopathy). The well-informed anaesthetist should be better able to use blood products which, while they may be life saving, are neither innocuous nor inexpensive.

Blood Component Transfusion↗

[Microbial safety of blood products].

OBJECTIVE: Septicemia caused by contaminated stored blood is a rare event, and the actual incidence is hard to determine due to a considerable variation of the different study protocols. This review is intended to give an overview of the pertinent literature considering causes, frequencies and kind of agents in contaminated blood products. SOURCES: English and German literature as well as own data. SELECTION CRITERIA: Original and review articles relevant to the topic. FINDINGS: The rate of septic episodes after transfusion of contaminated blood donations is approximately 0.3% (0.003-5%) of all blood transfusions. Contaminations of red cell preparations are predominantly caused by gram-negative bacteria, most often psychrophiles (Pseudomonas sp. Yersinia enterocolitica, Serratia). In platelet concentrates the prevailing bacterial organisms are represented by staphylococcal species. Bacterial contamination of blood and blood products may be generated in the process of blood collection and preparation of blood components. Materials and machinery used for blood processing may well serve as sources of contaminations. A considerable proportion of all contaminations must be attributed to transient, asymptomatic bacteremia of the donor. An additional predonation questionnaire addressing clinical symptoms associated with various pathological conditions (abdominal pain, tick-bites, malaria) has proven unpractical and may lead to a rejection rate of donors as high as 11%. CONCLUSIONS: In-process bacteriological surveillance, stringent control of technical and hygienic conditions, and the use of leukocyte filters can reduce the risk of bacteria transmission. In case of transfusion reactions due to suspected bacterial contamination, blood samples of the patient as well as of the transfused blood product and the transfusion equipment used must be secure for microbiological examination.

Blood Banks↗

[Use and preparation of thrombocyte concentrates].

Blood component transfusion therapy is an achievement of up-to-date transfusiology and is possible due to plastic equipment, centrifuge with air conditioning and modern technology which enables splitting blood into its components. Platelet concentration is a preparation of platelets gained from one unit of the whole blood and is used in therapy of patients with thrombocytopenias and thrombocytopathies. It can be preserved, depending on plastic bags, from 1 to 5 days with rotation on 22 degrees Celsius. This paper presents two methods of platelet concentration preparation (out of thrombocytes rich plasma and buffy coat) contribution of thrombocytes in concentrations and contamination of concentration with leucocytes, as well as changes during 72 hours of concentration preservation. One hundred units of thrombocytes had an average volume 51.42 ml. Platelet concentration gained out of thrombocyte rich plasma was 0.98 x 1011/l, and 0.80 x 109/l leucocytes. The number of thrombocytes in concentrations from buffy coat was 0.82 x 101/l, and 0.10 x 109/l leucocytes. Plasma pH after preparation was 7.21, and three days of conservation later it was 6.68. During these 72 hours of preserving the concentration there has not been a significant decrease in regard to the number of thrombocytes.

Humans↗

Posttransfusion hepatitis in Japan.

The incidence of posttransfusion hepatitis and the rate of chronicity were investigated in a program devised at our hospital in December, 1982. Out of 2,596 blood recipients between January, 1982, and December, 1987, 451 (22.7%) developed posttransfusion hepatitis. Seventy-seven patients out of 217 (35.3%) whose course was closely followed progressed to chronicity. The incidence of posttransfusion hepatitis increased with the volume of transfused blood without any evident limitation. Recipients of elevated-ALT donor blood (greater than 26 Karmen units) were found to be more susceptible to posttransfusion hepatitis than those who had received only normal-ALT donor blood. Packed red blood cells, whole blood and fresh whole blood were high-risk components, and fresh frozen plasma a low-risk component of blood. The carrier rate of non-A, non-B hepatitis agents in Japanese healthy blood donors was determined to be 1.2% using the Frost-Reed model of infectious diseases. Anti-hepatitis C virus was detected in 62% of the cases of posttransfusion hepatitis 1 year after transfusion.

Acute Disease↗

[Audit of labile blood product supplies].

An audit of the quality control system is part of an ongoing improvement process. The hospital-based facilities for the transfusion services not involved in collecting and processing donor blood but issuing blood cell products are expected to achieve quality standards. A quality control audit is considered an essential tool to assess and improve deficiencies or deviations for greater effectiveness. A global approach to transfusion processes added to a strict follow-up by all concerned are necessary for the proper management of transfusion practices and the risks involved. Its function is to achieve a certain quality of health, thus requiring confidence and respect. The end result is to ensure blood transfusion safety.

Biological Products↗

The use of blood at a large Red Cross center; an evaluation of various aspects of utilization.

During the past ten years over 1,000,000 pints of blood have been collected at the Los Angeles Regional Red Cross Blood Center. In addition to the progressive increase in the number of whole blood transfusions there has been a greater use of specific blood elements which results in purposeful and economical hemotherapy. With the increased use of blood there has also been a growing awareness of transfusion reactions and dangers. Serious transfusion complications reported have been due to bacterial contamination, to hemolytic reactions, to homologous serum jaundice, and to a mistake in cross-matching. Surgeons and anesthetists must pay strict attention to the use of blood since anesthesia masks severe hemolytic transfusion reactions. At present there is no way of eliminating the danger of the transmission of virus disease (infectious hepatitis and homologous serum jaundice) in blood transfusions.

Blood Banks↗

Significant reduction in blood loss in patients undergoing minimal extracorporeal circulation.

Several recent studies have shown differences in blood loss and allogeneic transfusion requirements between on-pump and off-pump coronary artery bypass grafting (CABG). Recently a new concept, the mini-extracorporeal circulation, was introduced to minimize the side effects of extracorporeal circulation. Therefore, there are no data comparing the three techniques with special emphasis to blood loss and transfusion requirements. Two hundred and eighty-five patients undergoing first-time coronary artery bypass grafting were retrospectively matched for number of grafts, age and sex. Ninety-five patients underwent surgery with the off-pump CABG (OPCAB) technique, 97 patients using conventional CABG with cold cardioplegia (CCABG) and 93 patients with the mini-extracorporeal circuit with warm blood cardioplegia (MCABG). Blood loss for the CCABG group with a mean loss of 819 +/- 557 mL and the OPCAB group with a mean loss of 870 +/- 768 mL was significant different compared to the MCABG group with a mean loss of 679 +/- 290 mL. The use of units red blood cell units was significantly higher for CCABG group and OPCAB group compared to the MCABG group. On the day of operation the use of platelet concentrate was significantly higher for the CCABG group compared to MCABG group. As a consequence of improvements of several components of the mini heart lung machine, significantly less blood products are needed in MCABG patients. The expected reduced need for transfusion when the pump was completely avoided could not be confirmed in this single retrospective cohort study.

Aged↗

Filtering out the confusion about leukocyte-poor blood components.

During the past decade, intensive investigation into the adverse clinical potential of leukocytes in red cell and platelet products has been undertaken. Clinical data indicated several benefits associated with the delivery of leukocyte-depleted blood products. These benefits include a reduction in nonhemolytic febrile transfusion reactions, human leukocyte antigen alloimmunization, and viral transmission. In response to such findings, several procedures and devices have been designed to remove leukocytes from blood components.

Blood Component Transfusion↗